Varian Creates Patient Education Web Site

Publication
Article
OncologyONCOLOGY Vol 13 No 1
Volume 13
Issue 1

Varian has created a new patient education Internet web site containing information on cancer radiotherapy treatments.

Varian has created a new patient education Internet web site containing information on cancer radiotherapy treatments. The site includes information from the National Cancer Institute and leading cancer treatment centers. Varian’s cancer patient education web site is located at www.varian.com/hcs /rad.

Articles in this issue
Varian Creates Patient Education Web Site
M. D. Anderson Researchers to Study Quality of Life in Testicular Cancer Patients
Follow-up Essential for Positive Home HIV Test Results
FDA Treads Delicate Line Between Safety and Speed
Estrogen May Reduce Colorectal Cancer Risk in Postmenopausal Women
Surgeons Issue Consensus Statement on Performing Sentinel Lymph Node Biopsy
Sentinel Lymph Node Mapping in Breast Cancer
Komen Foundation Receives Grant to Develop New Breast Imaging Technology
New Imaging Agent Seems to Enhance Detection of Metastatic Breast Cancer
NCI to Sponsor Phase III Trials of Liquid Shark Cartilage Angiogenesis Inhibitor
Aspirin Decreases Genetic Mutations Associated With Inherited Colon Cancer
Open Lung Biopsy Cost-Effective in Evaluating Solitary Pulmonary Nodules
Sentinel Lymph Node Mapping in Breast Cancer
Chemoprevention of Colorectal Cancer: Dietary and Pharmacologic Approaches
Clinical Status and Optimal Use of Amifostine
Recent Videos
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
9 Experts are featured in this series.
9 Experts are featured in this series.
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
2 experts are featured in this series.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
9 Experts are featured in this series.
Related Content
The updated labeling also includes new information on the recommended dosage of fludarabine phosphate when given with cyclophosphamide and rituximab.

FDA Updates Fludarabine Phosphate Labeling in Chronic Lymphocytic Leukemia

Russ Conroy
November 21st 2024
Article

The updated labeling also includes new information on the recommended dosage of fludarabine phosphate when given with cyclophosphamide and rituximab.

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

Collaboration Fosters Treatment Advancements for Young Lymphoma Populations

Andrew M. Evens, DO, MS
November 18th 2024
Podcast

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

Multiple Myeloma Experts Face Off on Sequencing Therapy Options

Multiple Myeloma Experts Face Off on Sequencing Therapy Options

ONCOLOGY Staff
November 21st 2024
Article

Experts in multiple myeloma gathered to debate current treatment options in the space during a recent Face Off.

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

Educating Patients and Clinicians on End-of-Life Care and Discussions

Kelley A. Rone, DNP, RN, AGNP-c
November 11th 2024
Podcast

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

Results from the TRIDENT-1 and CARE trials, which showcased durable activity and robust responses with repotrectinib, supported the recommendation.

EU Approval Recommended for Repotrectinib in ROS1+ NSCLC, NTRK+ Solid Tumors

Roman Fabbricatore
November 20th 2024
Article

Results from the TRIDENT-1 and CARE trials, which showcased durable activity and robust responses with repotrectinib, supported the recommendation.

For patients with NSCLC, subcutaneous pembrolizumab appeared noninferior vs intravenous pembrolizumab for study end points when combined with chemotherapy.

Subcutaneous Pembrolizumab/Chemo Meets Pharmacokinetic Endpoints in NSCLC

Tim Cortese
November 20th 2024
Article

For patients with NSCLC, subcutaneous pembrolizumab appeared noninferior vs intravenous pembrolizumab for study end points when combined with chemotherapy.